Are You Doing Your Best for Osteoporosis Patients? Optimising Osteoporosis Management and Facilitating Medication Adherence - QI&CPD - Category 2
An Australian Institute of Health and Welfare (AIHW) report based on pharmaceutical benefits scheme (PBS) data found that 25% of people prescribed oral bisphosphonates for osteoporosis stopped receiving their medication supply within six months and 10% of people only received one supply of medication. For oral bisphosphonates to be effective, they need to be taken consistently for 36 to 60 consecutive months. In high-risk patients, the duration of treatment with oral bisphosphonates needs to be even longer.
This activity has been approved by The Royal Australian College of General Practitioners QI&CPD Program. Total Points: 4.00 Point(s) (Category 2)
Mater Hill Family Medical Centre
Professor Gustavo Duque
MD, PhD, FRACP
Professor and Chair of Medicine,
The University of Melbourne, VIC
Senior Staff Specialist
Western Health, St. Albans, VIC
MBBS, FRACP, MSCOA
PhD Candidate Bone Biology Division
Garvan Institute of Medical Research,
Visiting Medical Officer St Vincent’s Hospital
Bone and Calcium Outpatient Clinic, Sydney NSW
Endocrinologist Sydney Medical Specialist, Sydney NSW
On completion of this program, participants will be better able to:
- Describe the risks of poor adherence to osteoporosis treatments and communicate these risks to patients.
- Review the issues underlying patient behaviours and attitudes towards osteoporosis treatment, particularly factors that lead to treatment cessation.
- Improve recall, reassessment and management of patients who have poor adherence and persistence with osteoporosis treatment.